Breast cancer represents a particularly compelling application for radioiodide treatment due to increased endogenous NIS expression in most tumours (70–80%) (3, 4, 5), including triple negative breast cancer (TNBC) (6) and metastases (7, 8), which are often resistant to standard treatments. This evidence concerns the gene SLC5A5 and neoplasm.